Compare PBF & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBF | LQDA |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2012 | 2018 |
| Metric | PBF | LQDA |
|---|---|---|
| Price | $26.10 | $34.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $30.64 | ★ $37.40 |
| AVG Volume (30 Days) | ★ 2.6M | 1.1M |
| Earning Date | 02-12-2026 | 11-03-2025 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,544,100,000.00 | $69,216,000.00 |
| Revenue This Year | N/A | $994.17 |
| Revenue Next Year | $3.13 | $169.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 343.41 |
| 52 Week Low | $13.62 | $11.26 |
| 52 Week High | $41.48 | $36.41 |
| Indicator | PBF | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 28.55 | 55.31 |
| Support Level | $25.90 | $33.45 |
| Resistance Level | $26.95 | $36.60 |
| Average True Range (ATR) | 1.17 | 1.41 |
| MACD | -0.17 | -0.25 |
| Stochastic Oscillator | 9.10 | 47.88 |
PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines and storage facilities. The Logistics segment consists solely of PBFX's operations.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.